These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24378784)

  • 61. Preparing individual patient data from clinical trials for sharing: the GlaxoSmithKline approach.
    Hughes S; Wells K; McSorley P; Freeman A
    Pharm Stat; 2014; 13(3):179-83. PubMed ID: 24668938
    [TBL] [Abstract][Full Text] [Related]  

  • 62. New CMAJ policy on sharing data from clinical research.
    Fletcher J
    CMAJ; 2014 Feb; 186(3):163. PubMed ID: 24491477
    [No Abstract]   [Full Text] [Related]  

  • 63. UK Parliament calls for sharing of all clinical trial data.
    Collier R
    CMAJ; 2014 Feb; 186(3):176. PubMed ID: 24418977
    [No Abstract]   [Full Text] [Related]  

  • 64. iEdgeDTA: integrated edge information and 1D graph convolutional neural networks for binding affinity prediction.
    Suviriyapaisal N; Wichadakul D
    RSC Adv; 2023 Aug; 13(36):25218-25228. PubMed ID: 37636509
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up.
    Oswald E; Bug D; Grote A; Lashuk K; Bouteldja N; Lenhard D; Löhr A; Behnke A; Knauff V; Edinger A; Klingner K; Gaedicke S; Niedermann G; Merhof D; Feuerhake F; Schueler J
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483746
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cancer nanotechnology: current status and perspectives.
    Kemp JA; Kwon YJ
    Nano Converg; 2021 Nov; 8(1):34. PubMed ID: 34727233
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Not just an antibiotic target: Exploring the role of type I signal peptidase in bacterial virulence.
    Walsh SI; Craney A; Romesberg FE
    Bioorg Med Chem; 2016 Dec; 24(24):6370-6378. PubMed ID: 27769673
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Why is there no generic insulin? Historical origins of a modern problem.
    Greene JA; Riggs KR
    N Engl J Med; 2015 Mar; 372(12):1171-5. PubMed ID: 25785977
    [No Abstract]   [Full Text] [Related]  

  • 69. Building a wall against biosimilars.
    Nat Biotechnol; 2013 Apr; 31(4):264. PubMed ID: 23563397
    [No Abstract]   [Full Text] [Related]  

  • 70. Sequestration to slash research grants and delay biosimilars.
    Fox JL
    Nat Biotechnol; 2013 Apr; 31(4):271. PubMed ID: 23563405
    [No Abstract]   [Full Text] [Related]  

  • 71. 2013 in reflection.
    Mullard A
    Nat Rev Drug Discov; 2014 Jan; 13(1):5-7. PubMed ID: 24378784
    [No Abstract]   [Full Text] [Related]  

  • 72. [Development and perspective for the Biosimilar medicines].
    Takayasu Y; Tsukamoto T
    Nihon Yakurigaku Zasshi; 2016 May; 147(5):303-9. PubMed ID: 27181727
    [No Abstract]   [Full Text] [Related]  

  • 73. Developing oncology biosimilars: an essential approach for the future.
    Abraham J
    Semin Oncol; 2013 Dec; 40 Suppl 1():S5-24. PubMed ID: 24267944
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.